Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELDN Eledon Pharmaceuticals	$2.78 -1.1%	$3.04	$2.30 ▼ $5.54	$166.47M	-0.17	276,196 shs	199,424 shs
GHRS GH Research	$11.84 -1.3%	$10.99	$6.00 ▼ $20.50	$616.01M	0.97	189,481 shs	146,643 shs
KALV KalVista Pharmaceuticals	$12.31 +1.3%	$12.49	$7.30 ▼ $15.50	$612M	-0.01	463,005 shs	1.75 million shs
XNCR Xencor	$8.36 +0.6%	$9.07	$7.16 ▼ $27.24	$594.99M	0.87	667,672 shs	835,269 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELDN Eledon Pharmaceuticals	0.00%	-7.33%	-9.15%	-20.80%	+6.51%
GHRS GH Research	0.00%	-7.72%	-4.90%	-5.28%	-1.00%
KALV KalVista Pharmaceuticals	0.00%	-5.96%	+0.57%	+3.53%	+8.27%
XNCR Xencor	0.00%	-11.35%	+2.70%	-36.67%	-57.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELDN Eledon Pharmaceuticals	2.6773 of 5 stars	3.5	4.0	0.0	2.7	1.7	0.0
GHRS GH Research	1.598 of 5 stars	3.5	0.0	0.0	2.2	2.5	0.0
KALV KalVista Pharmaceuticals	3.9679 of 5 stars	3.6	0.0	4.4	2.9	2.5	0.6
XNCR Xencor	3.9081 of 5 stars	3.4	2.0	3.9	2.0	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELDN Eledon Pharmaceuticals	3.00	Buy	$9.00	223.74% Upside
GHRS GH Research	3.00	Buy	$32.00	170.27% Upside
KALV KalVista Pharmaceuticals	3.13	Buy	$24.83	101.73% Upside
XNCR Xencor	2.75	Moderate Buy	$28.00	234.93% Upside

Current Analyst Ratings Breakdown

Latest ELDN, GHRS, KALV, and XNCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ELDN Eledon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$9.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
5/13/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	GHRS GH Research	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $29.00
5/9/2025	GHRS GH Research	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/8/2025	XNCR Xencor	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$22.00 ➝ $6.00
4/30/2025	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
4/21/2025	XNCR Xencor	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/26/2025	KALV KalVista Pharmaceuticals	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.98 per share	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$4.86 per share	N/A
XNCR Xencor	$110.49M	5.38	N/A	N/A	$9.63 per share	0.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELDN Eledon Pharmaceuticals	-$36.18M	-$2.10	N/A	N/A	N/A	N/A	-79.54%	-41.62%	8/18/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$126.64M	-$3.72	N/A	N/A	N/A	N/A	-104.25%	-78.69%	7/10/2025 (Estimated)
XNCR Xencor	-$232.62M	-$3.06	N/A	N/A	N/A	-181.17%	-31.94%	-22.19%	8/4/2025 (Estimated)

Latest ELDN, GHRS, KALV, and XNCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	-$0.08	+$0.20	-$0.08	N/A	N/A
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/8/2025	Q1 2025	XNCR Xencor	-$0.60	-$0.66	-$0.06	-$0.66	$23.44 million	$32.73 million
3/20/2025	Q4 2024	ELDN Eledon Pharmaceuticals	-$0.32	-$0.64	-$0.32	-$0.64	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELDN Eledon Pharmaceuticals	N/A	13.90	13.91
GHRS GH Research	N/A	29.71	29.71
KALV KalVista Pharmaceuticals	N/A	10.44	10.44
XNCR Xencor	0.16	5.89	5.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELDN Eledon Pharmaceuticals	56.77%
GHRS GH Research	56.90%
KALV KalVista Pharmaceuticals	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ELDN Eledon Pharmaceuticals	12.30%
GHRS GH Research	41.60%
KALV KalVista Pharmaceuticals	10.50%
XNCR Xencor	4.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.52 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
KALV KalVista Pharmaceuticals	100	49.72 million	44.50 million	Optionable
XNCR Xencor	280	71.17 million	67.78 million	Optionable

ELDN, GHRS, KALV, and XNCR Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 5.7% on Insider Selling

June 18 at 1:31 AM | americanbankingnews.com

Xencor (NASDAQ:XNCR) Shares Down 5.7% on Insider Selling

June 17 at 11:43 AM | marketbeat.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 17 at 5:04 AM | insidertrades.com

Insider Selling: Xencor, Inc. (NASDAQ:XNCR) Director Sells 2,215 Shares of Stock

June 16, 2025 | marketbeat.com

Kurt A. Gustafson Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Sells $27,595.46 in Stock

June 16, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Director Ellen Feigal Sells 2,993 Shares

June 16, 2025 | marketbeat.com

Analysts Set Xencor, Inc. (NASDAQ:XNCR) Target Price at $29.50

June 11, 2025 | americanbankingnews.com

Xencor (NASDAQ:XNCR) Trading Up 6.3% - Here's What Happened

June 10, 2025 | marketbeat.com

Bank of America Corp DE Sells 585,930 Shares of Xencor, Inc. (NASDAQ:XNCR)

June 9, 2025 | marketbeat.com

27,491 Shares in Xencor, Inc. (NASDAQ:XNCR) Acquired by Wellington Management Group LLP

June 8, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 8, 2025 | marketbeat.com

Public Employees Retirement System of Ohio Purchases New Holdings in Xencor, Inc. (NASDAQ:XNCR)

June 3, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Nuveen Asset Management LLC Purchases 685,557 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 26, 2025 | marketbeat.com

Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC

May 26, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR)

May 25, 2025 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)

May 13, 2025 | theglobeandmail.com

Xencor Reports First Quarter 2025 Financial Results

May 7, 2025 | uk.finance.yahoo.com

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

May 7, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, GHRS, KALV, and XNCR Company Descriptions

Eledon Pharmaceuticals NASDAQ:ELDN

$2.78 -0.02 (-0.89%)

As of 06/18/2025 04:00 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

GH Research NASDAQ:GHRS

$11.84 -0.15 (-1.25%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.88 +0.04 (+0.30%)

As of 06/18/2025 07:23 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

KalVista Pharmaceuticals NASDAQ:KALV

$12.31 +0.16 (+1.32%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$12.32 +0.00 (+0.04%)

As of 06/18/2025 07:58 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Xencor NASDAQ:XNCR

$8.36 +0.05 (+0.60%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$8.52 +0.16 (+1.85%)

As of 06/18/2025 06:07 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time